Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
CNTB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Connect Biopharma Holdings LimitedNASDAQ: CNTB
EBITDA · Q4 FY2025 · quarter ended Dec 2025
EBITDA remains negative
Q4 FY2025 EBITDA was -$14.9M, compared with -$8.64M a year earlier.
Context
- EBITDA amounted to 85279.7% of revenue in FY2025, up 85223.0 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$54.42M (+0.3%) for the fiscal year ending Dec 2026, a step up from the -270.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$14.9M— QoQ
- Last fiscal yearDec 2025
- -$54.58M-270.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -72.4% | — | — |
| 1 year | -270.2% | +0.3% | +270.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (54.58M) USD
- Year-over-year change
- -270.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (54.58M) | -270.2% |
| FY2024 | 2024-12-31 | (14.75M) | +75.9% |
| FY2023 | 2023-12-31 | (61.27M) | +47.5% |
| FY2022 | 2022-12-31 | (116.74M) | +42.0% |
| FY2021 | 2021-12-31 | (201.36M) | — |
EBITDA vs competitors
How CNTB compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -270.2% is the lowest of 9, against a peer median of +4.7%.
- EBITDA amounts to 85279.7% of revenue for CNTB, versus a peer median of 2480.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$24M USD | +7.8% | — | 337.0% | |
| LTM Mar 2026 | -$40.18M USD | -45.5% | — | — | |
| LTM Mar 2026 | -€42.36M EUR | +1.6% | — | 144435.8% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$44.08M USD | +36.5% | — | — |
| LTM Mar 2026 | -$46.23M USD | +30.8% | — | 4623.1% | |
IMAImageneBio Inc | LTM Mar 2026 | -$51.64M USD | -7.8% | — | — |
| FY2025 | -$54.58M USD | -270.2% | — | 85279.7% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$84.44M USD | -35.4% | — | — |
| LTM Mar 2026 | -$106.12M USD | +42.0% | — | 106.5% | |
| Peer median (excluding CNTB) | — | +4.7% | — | 2480.0% | |
Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 26.03M | 64K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 26.03M | 64K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 80.5M | 96.63M | 53M | 29.26M | 37.8M |
| Selling, General & Admin | 19.01M | 20.81M | 16.05M | 19.23M | 20.34M |
| Operating Expenses | 98.11M | 119.32M | 69.06M | 48.49M | 58.14M |
| Depreciation & Amortization | 634K | 1.03M | 720K | 660K | 704K |
| EBITDA | (201.36M) | (116.74M) | (61.27M) | (14.75M) | (54.58M) |
| EBITDA Margin | — | — | — | -56.6% | -85279.7% |
| Operating Income | (98.11M) | (119.32M) | (69.06M) | (22.45M) | (58.07M) |
| Operating Margin | — | — | — | -86.2% | -90740.6% |
| Interest Income | 97.67K | 1.56M | 5.2K | 4.45M | 2.27M |
| Interest Expense | 6.91K | 21.03K | 0 | 0 | 0 |
| Other Income / Expenses | (103.89M) | 1.52M | 7.07M | 7.05M | 2.79M |
| Income Before Tax | (202M) | (117.79M) | (61.99M) | (15.41M) | (55.28M) |
| Pre-Tax Margin | — | — | — | -59.2% | -86379.7% |
| Income Tax Expense | 266K | 298K | 120K | 223K | 197K |
| Net Income | (202.27M) | (118.09M) | (62.11M) | (15.63M) | (55.48M) |
| Net Margin | — | — | — | -60.0% | -86687.5% |
| EPS (Basic) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| EPS (Diluted) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| Weighted Avg Shares | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
| Weighted Avg Shares (Diluted) | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
Connect Biopharma Holdings Limited
NASDAQ:CNTB
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.